Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
D DERMATOLOGICALS
D11 OTHER DERMATOLOGICAL PREPARATIONS
D11A OTHER DERMATOLOGICAL PREPARATIONS
D11AH Agents for dermatitis, excluding corticosteroids
D11AH11 Delgocitinib
D11046 Delgocitinib (JAN/USAN/INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
26 Epidermides
269 Miscellaneous
2699 Others
D11046 Delgocitinib (JAN/USAN/INN)
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG02020 JAK inhibitor
D11046 Delgocitinib
Dermatological agent
DG03243 Atopic dermatitis agent
D11046 Delgocitinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D11046 Delgocitinib
DG02925 CYP3A5 substrate
D11046 Delgocitinib
Drug classes [BR:br08332]
Immunological agent
DG02020 JAK inhibitor
D11046 Delgocitinib
Antirheumatic agent
DG01985 Disease modifying anti-rheumatic drug (DMARD)
D11046 Delgocitinib
Dermatological agent
DG03243 Atopic dermatitis agent
D11046 Delgocitinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Non-receptor tyrosine kinases
JAK family
JAK1
D11046 Delgocitinib (JAN/USAN/INN) <JP/US>
JAK2
D11046 Delgocitinib (JAN/USAN/INN) <JP/US>
JAK3
D11046 Delgocitinib (JAN/USAN/INN) <JP/US>
TYK2
D11046 Delgocitinib (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11046
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11046
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11046
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11046
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11046